Path Active; Safety and Tolerability Study (PASTS)

April 9, 2024 updated by: Richard Leigh, Royal Free Hospital NHS Foundation Trust
Path Active™ comprises a pair of monitoring insoles which measure parameters associated with foot ulceration in diabetes: temperature and pressure. The insoles are linked via an app to the wearer's mobile phone and also to a clinical dashboard so that both wearer and clinician are alerted to early signs of skin damage on the foot so that immediate preventive action can be taken. The study will assess safety and tolerability of Path Active™ in 10 users, who have been assessed as having a 'high risk' of foot ulceration, over a period of 7 days.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Foot complications in people with diabetes are the most common cause of non-traumatic leg amputation in the UK with over 176 leg, toe or foot amputations every week in England. One in seven people with diabetes will develop a foot ulcer at some stage in their lives. Not only does this impair their daily activities and reduce their quality of life, it also increases their risk of amputation by up to 24-fold. Five year mortality for minor and major amputations in diabetes have been reported as 46.2% and 56.6%, respectively. Circulatory problems, nerve impairment and infection contribute to foot complications in diabetes. Prior to a foot ulceration, changes in temperature and/or pressure occur. These early warning signs can be measured by Path Active™ and alert the wearer via a mobile phone app and the clinician via a clinical dashboard so that preventive action can be taken. Currently people with diabetes who have been assessed as 'high risk' for foot ulceration are allocated appointments with podiatrists in 'foot protection teams' who review on a weekly to monthly basis. Path Active™ has the potential to reduce appointments by alerting podiatry teams to potential problems as they occur rather than regular routine reviews. Path Active™ may be able to reduce hospital and clinic visits and thereby reduce healthcare carbon footprint.

The primary objective of this clinical investigation is to evaluate the safety and tolerability of Path Active™ in people with diabetes who are at 'high risk' of foot ulceration.

Study Type

Interventional

Enrollment (Actual)

5

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participant able to give informed consent.
  • Age >18 at the time of consent.
  • Diagnosis of Type 1 or Type 2 Diabetes.
  • Both Feet Intact (no ulceration).
  • Participant understands and is willing to participate and can comply with the follow-up regime.
  • Participant diabetes foot Risk Stratification as 'High Risk'.
  • Ability to walk independently for > 100 metres i.e without use of wheelchair, walking stick or personal assistance.
  • Participant able and willing to wear suitable footwear.
  • Most own a mobile phone and be willing to upload WWP app.

Exclusion Criteria:

  • Either foot has less than 2 arterial vessel run-off on Doppler.
  • Poor visual acuity ie registered blind, unless supported by carer.
  • Current participation in another clinical investigation of a medical device or a drug; or participation in such a study within 30 days prior to study enrolment.
  • Body Mass Index (BMI) >40.
  • Participant has bespoke contact insoles and footwear.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Path Active
All participants will use the device. There is no comparator.
Device: Path Active
Participant use of Path Active insoles, mobile phone app and clinician's dashboard (where pressure and temperature changes can be reviewed by a clinician). Participants will complete a patient questionnaire relating to use of the device and EuroQol - EQ5D at the beginning and end of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: 3 months (Participants will wear the device for a minimum of 7 days)
The primary objective of this clinical investigation is to evaluate any adverse events whilst using Path Active™ in people with diabetes who are at 'high risk' of foot ulceration.
3 months (Participants will wear the device for a minimum of 7 days)
Device questionnaire
Time Frame: 3 months (Participants will wear the device for a minimum of 7 days)
Participants will complete study questionnaires relating to the product (ease of use, use of the mobile phone app, use of the insoles, action taken relating to app warnings)
3 months (Participants will wear the device for a minimum of 7 days)
Changes Quality of Life Measurement
Time Frame: 3 months (Participants will wear the device for a minimum of 7 days)

EuroQol EQ-5D-5L assessment for quality of life assessment at the beginning and end of the study period.

The EQ-5D-5L health profile includes the items mobility (MO), self-care (SC), usual activities (UA), pain/discomfort (PD) and anxiety/depression (AD). The EQ-5D-5L asks respondents to endorse one of five response levels for each item: "no problems," "slight problems," "moderate problems," "severe problems," and "extreme problems"/ "unable to", describing 3125 (55) health state profiles. The instrument also includes a visual analog scale (VAS) anchored by 0 (worst imaginable health) and 100 (best imaginable health) that will be analysed separately from the health profile.
3 months (Participants will wear the device for a minimum of 7 days)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction in CO2 comparing carbon dioxide emitted due to ulcer treatment vs carbon dioxide emitted due to device manufacture
Time Frame: 3 months (Participants will wear the device for a minimum of 7 days)
To model the carbon dioxide reduction that occurs if ulceration and the need for ulcer treatment is prevented. The carbon footprint for the manufacture and life span of the device will been calculated and the carbon footprint for ulcer treatment will be calculated. The difference between CO2 due to manufacture of the device will be compared with the CO2 required for ulcer treatment to show how much reduction in carbon can be made by preventing foot ulceration when using Path Active.
3 months (Participants will wear the device for a minimum of 7 days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Royal Free Hospital NHS Foundation Trust

Collaborators

Walk With Path

Investigators

  • Study Chair: Richard Leigh, BSc, Royal Free London NHS Foundation Trust

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2023

Primary Completion (Actual)

November 17, 2023

Study Completion (Actual)

November 24, 2023

Study Registration Dates

First Submitted

August 22, 2023

First Submitted That Met QC Criteria

October 11, 2023

First Posted (Actual)

October 16, 2023

Study Record Updates

Last Update Posted (Actual)

April 11, 2024

Last Update Submitted That Met QC Criteria

April 9, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 326601

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetic Foot

Clinical Trials on Path Active

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe